Pfizer/W-L hearing
This article was originally published in The Tan Sheet
Executive Summary
Preliminary injunction hearing date set for Jan. 24 regarding Pfizer's request to enjoin the Warner-Lambert/American Home Products proposed merger, which is set to occur May 15. In a separate complaint filed Nov. 23, Pfizer alleges W-L breached a "standstill agreement" that would compel it to accept the superior merger offer. Pfizer says the lawsuit has no effect on its ongoing Lipitor marketing agreement with W-L. In response to the complaints, Warner-Lambert asserts Pfizer is misstating the terms of the standstill agreement, which only is terminated if W-L is acquired by a third party, while the deal with AHP is a merger of equals. W-L continues to study the Lipitor agreement to decide further action
You may also be interested in...
AHP to sweeten bid?
American Home Products will offer "additional value" to its bid for Warner-Lambert if W-L is able to secure the marketing rights to the blockbuster Rx cholesterol-reducer Lipitor, AHP says in a Nov. 30 letter to Warner-Lambert. W-L, which shares marketing rights to Lipitor with Pfizer, filed a counterclaim in Delaware chancery court Nov. 29 to end the partnership as a result of "massive and intentional breaches by Pfizer." In response, Pfizer says it has not violated any agreements and contends Warner-Lambert "has engaged in a series of desperate defensive measures." A court date on Pfizer's request to enjoin the proposed W-L/AHP merger is set for Jan. 24 (1"The Tan Sheet" Nov. 29, In Brief). W-L sent a letter to its shareholders Dec. 2 explaining the recent events and supporting a union with AHP
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC